1996 Euro OTC Spending "Will Exceed $20 Billion"

26 May 1996

Spending by European consumers on over-the-counter medicines is forecast to exceed $20 billion this year, up 41% on spending in 1990, says a new study from James Dudley International.

This will represent a saving to European government health care schemes of over $9 billion, says the study, which is entitled The European Consumers' Usages and Attitudes to Self-Medication.

The study says about 25% of all European adults normally now choose to self-medicate for minor ailments rather than consult a doctor, while a further quarter tend not to treat at all. French, Spanish and German consumers are more likely than the British to consult their doctor for a minor ailment. The Swiss spend two and a half times the European average on OTC medicines, and Belgians spend twice as much, it says. Austrian, UK, Italian and Dutch consumers spend about 60% of the European average, while Poles and Hungarians spend one third.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight